Prognostic role of post-infarction C-reactive protein in patients undergoing implantation of cardioverter-defibrillators: Design of the C-reactive protein Assessment after Myocardial Infarction to GUide Implantation of DEfibrillator (CAMI GUIDE) study

Fulvio Bellocci, Luigi M. Biasucci, Gian Franco Gensini, Luigi Padeletti, Antonio Raviele, Massimo Santini, Giovanna Giubilato, Maurizio Landolina, Giuseppe Biondi-Zoccai, Giovanni Raciti, Massimo Sassara, Antonello Castro, Antoine Kheir, Filippo Crea

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Patients at risk of sudden cardiac death (SCD) after myocardial infarction (MI) can currently be offered effective means of prevention, such as implantable cardioverter-defibrillators (ICD). However, predictors of SCD able to identify those patients who are at higher risk are still lacking. Whether C-reactive protein (CRP), a serum inflammatory marker with established prognostic accuracy after MI, can also be a predictor of SCD is unclear. METHODS: The CAMI GUIDE study is designed to evaluate the prognostic role of CRP in patients undergoing ICD implantation after MI according to MADIT II criteria (i.e. left ventricular ejection fraction ≤ 30%). CAMI GUIDE is a prospective observational study aimed at assessing the role of CRP in the risk-stratification of SCD after MI. CRP will be measured on the basis of a pre-specified cut-off value of 3 mg/l, before and 1 month after ICD implantation; clinical follow-up will last 24 months. The primary endpoint is the combined rate of SCD or fast ventricular tachycardia/ventricular fibrillation. Secondary endpoints will be total mortality, death due to acute coronary syndromes, death from pump failure, non-fatal MI, coronary revascularization, hospitalization for congestive heart failure or unstable angina and inappropriate ICD shocks. Twenty-four Italian centers will participate in enrolment of the 290 patients planned according to power analysis. CONCLUSIONS: The CAMI GUIDE study will assess the predictive role of CRP in SCD in patients with previous MI undergoing ICD implantation. Its results will improve risk stratification, thereby enabling better-tailored and more cost-effective therapies to be undertaken in those patients whose need is greatest.

Original languageEnglish
Pages (from-to)293-299
Number of pages7
JournalJournal of Cardiovascular Medicine
Volume8
Issue number4
DOIs
Publication statusPublished - Apr 2007

Fingerprint

Defibrillators
C-Reactive Protein
Infarction
Sudden Cardiac Death
Myocardial Infarction
Implantable Defibrillators
Unstable Angina
Ventricular Fibrillation
Acute Coronary Syndrome
Ventricular Tachycardia
Stroke Volume
Observational Studies
Shock
Hospitalization
Heart Failure
Biomarkers
Prospective Studies
Costs and Cost Analysis
Mortality

Keywords

  • C-reactive protein
  • Myocardial infarction
  • Risk stratification
  • Sudden cardiac death

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Prognostic role of post-infarction C-reactive protein in patients undergoing implantation of cardioverter-defibrillators : Design of the C-reactive protein Assessment after Myocardial Infarction to GUide Implantation of DEfibrillator (CAMI GUIDE) study. / Bellocci, Fulvio; Biasucci, Luigi M.; Gensini, Gian Franco; Padeletti, Luigi; Raviele, Antonio; Santini, Massimo; Giubilato, Giovanna; Landolina, Maurizio; Biondi-Zoccai, Giuseppe; Raciti, Giovanni; Sassara, Massimo; Castro, Antonello; Kheir, Antoine; Crea, Filippo.

In: Journal of Cardiovascular Medicine, Vol. 8, No. 4, 04.2007, p. 293-299.

Research output: Contribution to journalArticle

Bellocci, Fulvio ; Biasucci, Luigi M. ; Gensini, Gian Franco ; Padeletti, Luigi ; Raviele, Antonio ; Santini, Massimo ; Giubilato, Giovanna ; Landolina, Maurizio ; Biondi-Zoccai, Giuseppe ; Raciti, Giovanni ; Sassara, Massimo ; Castro, Antonello ; Kheir, Antoine ; Crea, Filippo. / Prognostic role of post-infarction C-reactive protein in patients undergoing implantation of cardioverter-defibrillators : Design of the C-reactive protein Assessment after Myocardial Infarction to GUide Implantation of DEfibrillator (CAMI GUIDE) study. In: Journal of Cardiovascular Medicine. 2007 ; Vol. 8, No. 4. pp. 293-299.
@article{9b9ab868ce52416791ed1651d56c40f2,
title = "Prognostic role of post-infarction C-reactive protein in patients undergoing implantation of cardioverter-defibrillators: Design of the C-reactive protein Assessment after Myocardial Infarction to GUide Implantation of DEfibrillator (CAMI GUIDE) study",
abstract = "BACKGROUND: Patients at risk of sudden cardiac death (SCD) after myocardial infarction (MI) can currently be offered effective means of prevention, such as implantable cardioverter-defibrillators (ICD). However, predictors of SCD able to identify those patients who are at higher risk are still lacking. Whether C-reactive protein (CRP), a serum inflammatory marker with established prognostic accuracy after MI, can also be a predictor of SCD is unclear. METHODS: The CAMI GUIDE study is designed to evaluate the prognostic role of CRP in patients undergoing ICD implantation after MI according to MADIT II criteria (i.e. left ventricular ejection fraction ≤ 30{\%}). CAMI GUIDE is a prospective observational study aimed at assessing the role of CRP in the risk-stratification of SCD after MI. CRP will be measured on the basis of a pre-specified cut-off value of 3 mg/l, before and 1 month after ICD implantation; clinical follow-up will last 24 months. The primary endpoint is the combined rate of SCD or fast ventricular tachycardia/ventricular fibrillation. Secondary endpoints will be total mortality, death due to acute coronary syndromes, death from pump failure, non-fatal MI, coronary revascularization, hospitalization for congestive heart failure or unstable angina and inappropriate ICD shocks. Twenty-four Italian centers will participate in enrolment of the 290 patients planned according to power analysis. CONCLUSIONS: The CAMI GUIDE study will assess the predictive role of CRP in SCD in patients with previous MI undergoing ICD implantation. Its results will improve risk stratification, thereby enabling better-tailored and more cost-effective therapies to be undertaken in those patients whose need is greatest.",
keywords = "C-reactive protein, Myocardial infarction, Risk stratification, Sudden cardiac death",
author = "Fulvio Bellocci and Biasucci, {Luigi M.} and Gensini, {Gian Franco} and Luigi Padeletti and Antonio Raviele and Massimo Santini and Giovanna Giubilato and Maurizio Landolina and Giuseppe Biondi-Zoccai and Giovanni Raciti and Massimo Sassara and Antonello Castro and Antoine Kheir and Filippo Crea",
year = "2007",
month = "4",
doi = "10.2459/01.JCM.0000263496.52656.95",
language = "English",
volume = "8",
pages = "293--299",
journal = "Journal of Cardiovascular Medicine",
issn = "1558-2027",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Prognostic role of post-infarction C-reactive protein in patients undergoing implantation of cardioverter-defibrillators

T2 - Design of the C-reactive protein Assessment after Myocardial Infarction to GUide Implantation of DEfibrillator (CAMI GUIDE) study

AU - Bellocci, Fulvio

AU - Biasucci, Luigi M.

AU - Gensini, Gian Franco

AU - Padeletti, Luigi

AU - Raviele, Antonio

AU - Santini, Massimo

AU - Giubilato, Giovanna

AU - Landolina, Maurizio

AU - Biondi-Zoccai, Giuseppe

AU - Raciti, Giovanni

AU - Sassara, Massimo

AU - Castro, Antonello

AU - Kheir, Antoine

AU - Crea, Filippo

PY - 2007/4

Y1 - 2007/4

N2 - BACKGROUND: Patients at risk of sudden cardiac death (SCD) after myocardial infarction (MI) can currently be offered effective means of prevention, such as implantable cardioverter-defibrillators (ICD). However, predictors of SCD able to identify those patients who are at higher risk are still lacking. Whether C-reactive protein (CRP), a serum inflammatory marker with established prognostic accuracy after MI, can also be a predictor of SCD is unclear. METHODS: The CAMI GUIDE study is designed to evaluate the prognostic role of CRP in patients undergoing ICD implantation after MI according to MADIT II criteria (i.e. left ventricular ejection fraction ≤ 30%). CAMI GUIDE is a prospective observational study aimed at assessing the role of CRP in the risk-stratification of SCD after MI. CRP will be measured on the basis of a pre-specified cut-off value of 3 mg/l, before and 1 month after ICD implantation; clinical follow-up will last 24 months. The primary endpoint is the combined rate of SCD or fast ventricular tachycardia/ventricular fibrillation. Secondary endpoints will be total mortality, death due to acute coronary syndromes, death from pump failure, non-fatal MI, coronary revascularization, hospitalization for congestive heart failure or unstable angina and inappropriate ICD shocks. Twenty-four Italian centers will participate in enrolment of the 290 patients planned according to power analysis. CONCLUSIONS: The CAMI GUIDE study will assess the predictive role of CRP in SCD in patients with previous MI undergoing ICD implantation. Its results will improve risk stratification, thereby enabling better-tailored and more cost-effective therapies to be undertaken in those patients whose need is greatest.

AB - BACKGROUND: Patients at risk of sudden cardiac death (SCD) after myocardial infarction (MI) can currently be offered effective means of prevention, such as implantable cardioverter-defibrillators (ICD). However, predictors of SCD able to identify those patients who are at higher risk are still lacking. Whether C-reactive protein (CRP), a serum inflammatory marker with established prognostic accuracy after MI, can also be a predictor of SCD is unclear. METHODS: The CAMI GUIDE study is designed to evaluate the prognostic role of CRP in patients undergoing ICD implantation after MI according to MADIT II criteria (i.e. left ventricular ejection fraction ≤ 30%). CAMI GUIDE is a prospective observational study aimed at assessing the role of CRP in the risk-stratification of SCD after MI. CRP will be measured on the basis of a pre-specified cut-off value of 3 mg/l, before and 1 month after ICD implantation; clinical follow-up will last 24 months. The primary endpoint is the combined rate of SCD or fast ventricular tachycardia/ventricular fibrillation. Secondary endpoints will be total mortality, death due to acute coronary syndromes, death from pump failure, non-fatal MI, coronary revascularization, hospitalization for congestive heart failure or unstable angina and inappropriate ICD shocks. Twenty-four Italian centers will participate in enrolment of the 290 patients planned according to power analysis. CONCLUSIONS: The CAMI GUIDE study will assess the predictive role of CRP in SCD in patients with previous MI undergoing ICD implantation. Its results will improve risk stratification, thereby enabling better-tailored and more cost-effective therapies to be undertaken in those patients whose need is greatest.

KW - C-reactive protein

KW - Myocardial infarction

KW - Risk stratification

KW - Sudden cardiac death

UR - http://www.scopus.com/inward/record.url?scp=34247169004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247169004&partnerID=8YFLogxK

U2 - 10.2459/01.JCM.0000263496.52656.95

DO - 10.2459/01.JCM.0000263496.52656.95

M3 - Article

C2 - 17413310

AN - SCOPUS:34247169004

VL - 8

SP - 293

EP - 299

JO - Journal of Cardiovascular Medicine

JF - Journal of Cardiovascular Medicine

SN - 1558-2027

IS - 4

ER -